Previous studies have demonstrated that STK33 is overexpressed in hypopharyngeal squamous cell carcinoma [20], hepatocellular carcinoma [21], human lung cancer [16,22,23], and pancreatic cancer [18] and the increased expression of STK33 may subsequently promote tumorigenesis and disease progression. This evidence concerns the gene STK33 and hepatocellular carcinoma.